At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 26 enrolled
Drug / intervention
Galcanezumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Anti-CGRP Neutralizing Antibody for Modulation of Neurogenic Inflammation in Trigeminal and Glossopharyngeal Pain Associated With Small Fiber Neuropathy/Fibromyalgia
In Brief
A Phase 4 clinical trial evaluating Galcanezumab for Trigeminal Neuralgia and Glossopharyngeal Neuralgia. Completed, enrolled 26 participants across 1 site.
Detailed Summary
The investigators will treat patients (targeting enrollment of n=20) who suffer from trigeminal or glossopharyngeal nerve pain in the context of painful small fiber neuropathy. The primary pain-related objective is reduction of pain and reduced use of rescue and other anti-pain medications. Another goal is to monitor and confirm the safety profile established in the migraine population, during previous Phase 3 trials.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTrigeminal Neuralgia, Glossopharyngeal Neuralgia
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartJul 2020
Primary CompletionJan 2023
TodayJul 2026
First PostedNov 12, 2019
Enrollment StartJul 24, 2020
Primary CompletionJan 4, 2023
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 6.6 years ago
Interventions
Galcanezumabdrug
Injection of study drug at 3 timepoints (day 30, day 60, day 90)